Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

Annals of Hematology

Volumn 88, Issue 11, 2009, Pages 1141-1144

  Möller, Isabel ^a   Blum, Sabine ^a   Gattermann, Norbert ^a   Haas, Rainer ^a   Habersang, Kerstin ^a   Germing, Ulrich ^a   Kuendgen, Andrea ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BENZENE; THALIDOMIDE; TIPIFARNIB; VALPROIC ACID; DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG DERIVATIVE; FARNESYL TRANS TRANSFERASE; HISTONE DEACETYLASE; QUINOLONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; AGED; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; DISEASE COURSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INDUSTRIAL WORKER; LETTER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OCCUPATIONAL EXPOSURE; POLYNEUROPATHY; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; DRUG ANTAGONISM; DRUG COMBINATION;

AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; AZACITIDINE; BENZENE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG THERAPY, COMBINATION; FARNESYLTRANSTRANSFERASE; HISTONE DEACETYLASES; HUMANS; MALE; OCCUPATIONAL EXPOSURE; PLATELET COUNT; QUINOLONES; THALIDOMIDE; VALPROIC ACID;

EID: 70349436151     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0730-x     Document Type: Letter

References (17)

1. Fenaux P, Raza P, GJi Muft, Aul C, Germing U, Kantarijan H, Cripe L, Kerstens R, De Porre P, Kurzrock R (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high risk mds. Blood 109:4158-4163. doi: 10.1182/blood-2006-07-035725
2. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, List AF, Gore SD, Seymour JF, Hellstrom-Lindberg E, Bennet JM, Byrd JC, Backstrom JT, Zimmermann LS, McKenzie DR, Beach CL, Silverman LR (2007) Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimes: Results of the aza-001 phase III study. Blood 110:817. Abstract
3. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1-6. doi: 10.1038/sj.leu.2402330
4. Raza A, Meyer P, Dutt D (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965. doi: 10.1182/blood.V98.4.958
5. Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28:325-332. doi: 10.1016/j.leukres.2003.08.007
6. Beaupre DM, Kurzrock R (1999) Ras and leukemia: From basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071
7. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferaseinhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275(39):30451-30457. doi: 10.1074/ jbc.M003469200
8. Kurzrock R, Kantarijan HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM (2008) Phase I Study of alternate-week administration of tipifarnib in patients with MDS. Clin Cancer Res 14:509-514. doi: 10.1158/1078-0432.CCR-07-1532
9. Silverman LR, Holland JF, Demakos EP (1994) Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12
10. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440. doi: 10.1200/ JCO.2002.04.117
11. Kantarijan H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803. doi: 10.1002/cncr.21792
12. Kantarijan H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57. doi: 10.1182/blood-2006-05-021162
13. Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:S19-S23. doi: 10.1038/ sj.leu.2400526
14. Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962
15. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-695. doi: 10.1080/10428190701882146
16. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269. doi: 10.1182/blood-2003-12-4333
17. Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancie. Cancer 110:943-995. doi: 10.1002/cncr.22891